Document is current
Any future updates will be listed below
-
Authors
Bentz, Philipp https://orcid.org/0000-0002-6474-192X
Eyerich, Kilian
Skudlik, Christoph
Schröder-Kraft, Claudia
Löffler, Harald
Pföhler, Claudia
Leitz, Nicolas
Thölken, Karisa
Weisshaar, Elke
-
Funding
Funding for this research was provided by:
Deutsche Gesetzliche Unfallversicherung (FB 323)
- License Information
-
More Information
Article History
Received: 12 September 2025
Accepted: 19 January 2026
First Online: 9 February 2026
Declarations
:
: Philipp Bentz is a research associate in the research project supported by the German Social Accident Insurance (DGUV) and is funded through it. Kilian Eyerich is a shareholder of Dermagnostix and a speaker and/or advisory board member for AbbVie, Almirall, BMS, Janssen, Leo, Lilly, Novartis, Pfizer, Sanofi, and UCB. Elke Weisshaar is the principal investigator of the DGUV-supported research project FB 323 on the molecular classifier. Claudia Pföhler served as consultant and/or has received honoraria from Bristol-Myers Squibb, Merck Sharp and Dohme, Novartis, Sanofi, Sunpharma, Pierre Fabre, AbbVie, Kyona Kirin, and Amgen; and received travel support from Amgen, Merck Sharp and Dohme, Bristol-Myers Squibb, Pierre Fabre, Sunpharma, and Novartis outside the submitted work. Christoph Skudlik, Claudia Schröder-Kraft, Harald Löffler, Nicolas Leitz, and Karisa Thölken have nothing to disclose.
: The study was approved by the Heidelberg Ethics Committee (S-506/2019) and is in accordance with the Helsinki Declaration of 1975, as revised in 1983. All patients provided informed consent prior to taking part in this study. The patients in this manuscript have provided written informed consent for publication of their case details and photographs.
